HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Q2 2023 13F Holders as of 30 Jun 2023

Type / Class
Equity / Common Stock
Shares outstanding
123,650,000
Total 13F shares
123,025,101
Share change
-1,112,752
Total reported value
$4,439,170,134
Put/Call ratio
147%
Price per share
$36.07
Number of holders
368
Value change
-$50,628,033
Number of buys
178
Number of sells
186

Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q2 2023

As of 30 Jun 2023, HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by 368 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 123,025,101 shares. The largest 10 holders included BlackRock Inc., VANGUARD GROUP INC, Artisan Partners Limited Partnership, STATE STREET CORP, SNYDER CAPITAL MANAGEMENT L P, JPMORGAN CHASE & CO, MACQUARIE GROUP LTD, GEODE CAPITAL MANAGEMENT, LLC, Invesco Ltd., and GW&K Investment Management, LLC. This page lists 368 institutional shareholders reporting positions in this security for the Q2 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.